The importance of the economic aspects of Type I (insulin-dependent) diabetes management is increasing due to the rising health care costs, limited health care resources, increasing incidence and prevalence, and the potential to reduce incidence and progression of diabetes-related complications with optimal management [1±3]. Most clinical trials focus on short-to medium-term outcomes requiring the development of methods for forecasting long-term outcomes based on known short-term data. Additionally, improved diabetes management ofteninvolvesrelatively highamounts of short-term expenditure to avoid long-term complications, with the overall effect on total long-term costs being difficult to quantify empirically [4±6]. Diabetologia (2000) 
Disease modelling is one method to generate longterm health economic data in the absence of empirical data, based on the extrapolation of existing data [7] . Information generated by modelling studies can therefore help decision-makers to identify interventions with long-term effects that could be considered good ªvalue for moneyº [8] .
The Diabetes Control and Complications Trial (DCCT) compared conventional with intensive insulin therapy over a median follow-up period of 7.4 years [9] . Conventional therapy was defined as one or two daily subcutaneous injections of insulin, daily self-monitoring of urine or blood glucose, and education on diet and exercise. Patients attended their diabetes clinic every 3 months for a consultation with medical staff, a dietitian, and behavioural scientist. Intensive insulin therapy was defined as subcutaneous injected insulin three or more times daily, or continuous subcutaneous infusion with an insulin pump. The insulin dosage was adjusted according to the following factors: a) the results of self-monitoring of blood glucose done at least four times daily; b) daily dietary intake; and c) anticipated exercise. After an intensive education period (including 4 days of hospitalization and weekly telephone calls and clinic visits) during the first 2 months, patients attended the diabetes clinic every month. The goal of intensive insulin therapy was to maintain blood glucose concentrations as close as possible to the normal range [10] . Patients were screened for renal disease during the DCCT to monitor progression of microvascular disease rather than to facilitate appropriate therapy for nephropathy. Due to the prevailing clinical practice standards at the time of the DCCT patients were not routinely treated with angiotensin converting enzyme inhibitors (ACE) for microalbuminuria (MAU) or proteinuria, so the effect of addition of ACE to intensive therapy is not known. The DCCT did not assess progression from proteinuria to end-stage renal failure patients. Similarly, patients were monitored for the development and progression of diabetes-related microvascular ocular disease. The progression from proliferative retinopathy to blindness with or without retinal photocoagulation was not assessed.
Therefore, no long-term trials have been done that compare different management strategies from onset of diabetes through the development of microvascular disease and progression to end-stage disease over patients' lifetime. For this reason a disease model was developed to estimate medical and cost outcomes for the development of diabetes and related complications in Switzerland under different intervention strategies over the lifetime of patients. The model allows comparison of different combinations of interventions for which long-term studies have not been carried out, based on a synthesis of existing data. Using this technique, optimal lifetime treatment pathways can be identified, ensuring that the most appropriate treatment combinations are implemented. The hypothesis tested was: intensive insulin therapy and screening for ± and treatment of ± MAU or retinopathy or both in Type I diabetic patients will improve clinical outcomes in comparison with conventional insulin therapy alone, while being efficient in health economic terms.
Methods
An incremental cost-effectiveness analysis was carried out. The intervention strategy used as the basis for comparison was conventional insulin therapy alone (C), with no laser therapy for proliferative retinopathy, nor ACE inhibitor therapy for MAU or proteinuria. We compared seven intervention strategies with conventional therapy alone: conventional insulin therapy plus annual screening for proliferative retinopathy with 7-field fundus photography, and treatment with laser photocoagulation if proliferative retinopathy was detected (C + EYE); conventional insulin therapy plus annual screening for MAU with urine test strips, and treatment with Captopril 25 mg three times daily if MAU was detected (3 positive results) (C + ACE); conventional therapy plus both eye and MAU screening (C + EYE + ACE); intensive insulin therapy alone (I); insulin therapy plus annual screening for proliferative retinopathy with 7-field fundus photography, and treatment with laser photocoagulation if proliferative retinopathy was detected (I + EYE); intensive insulin therapy plus annual screening for MAU with urine test strips, and treatment with Captopril 25 mg three times daily if MAU was detected (I + ACE); and intensive insulin therapy plus both eye and MAU screening (I + EYE + ACE).
The disease process was modelled by seven Markov submodels, representing the development and consequences of renal disease, retinopathy, amputation, myocardial infarction, stroke, major hypoglycaemic events, and ketoacidosis. The course of the development of diabetes complications under a given clinical treatment strategy can be interpreted as a time series of clinical events and medical outcomes (e. g. incidence of complications, mortality). Different interventions or treatment strategies were reflected by the change of the key clinical variables and medical consequences, i. e. by a change of the incidence and severity of clinical events or progress of the disease. Key factors used in the calculation of transition probabilities are summarized (Table 1 ). The resulting incidence history of events was combined with a table of cost items related to interventions and events or complications due to the disease (Table 2). For each of these events, a series of related cost elements was built up. Total lifetime costs were calculated by summing over time and events. The clinical and cost outcomes for a typical cohort of newly diagnosed 19±year±old (the median age of onset of Type I diabetes in urban Swiss males [1] ) diabetic patients, with no baseline complications, baseline HbA 1 c of 8.5 %, total cholesterol (T-CHOL) of 200 mg/dl (5.2 mmol/l), high density lipoprotein cholesterol (HDL) 50 mg/dl (1.3 mmol/l), and a systolic blood pressure (SBP) of 110 mmHg were compared under the different management strategies described previously. Changes in SBP, T-CHOL and HDL from baseline levels followed population-based changes with age [11, 12] . Based on these parameters, probabilities for clinical events were retrieved from published literature. Costs for each of the alternative intervention strategies assessed were calculated from reported resource consumption [5] , and were adapted to the Swiss-specific situation by attaching relevant costs for equipment, investigations, procedures, medications, and hospitalisation [13±17]. Costs for complications were taken directly from published Swiss sources [14, 16, 18, 19] or, where no Swiss specific data were available, were calculated from published resource consumption reported from the United States, combined with Swiss-specific costs for the resources used. The perspective of the Swiss third party payer was taken. All costs were calculated in Swiss francs (CHF) expressed in 1996 values. Only direct medical costs were considered.
Outcomes calculated were survival functions, life expectancy, cumulative incidence of complications, and mean expected total lifetime costs of diabetes management and complication treatment per patient. Incremental cost-effectiveness ratios for each intervention strategy were calculated in comparison with conventional insulin therapy alone, using the formula: (TC s -TC c ) / (LE s ± LE c ), where TC = the mean expected total lifetime direct costs, LE = life expectancy from baseline age expressed in years, s = the strategy being compared with conventional insulin therapy alone, and c = conventional insulin therapy alone.
Both undiscounted and discounted costs and clinical outcomes (life-years gained compared with conventional therapy only) were calculated. Due to controversy over which discount rates to use [7, 8, 20, 21] , analyses were done with discounted rates of 3, 5 and 6 % for both cost and clinical outcomes.
Intensive insulin therapy resulted in a reduction of all macrovascular events combined by 41 % (p = 0.06) [9] . The DCCT, however, was not primarily designed to assess macrovascular outcomes, and with a relativety young patient population and short follow-up time, it was unlikely to show important differences in incidence of macrovascular disease. It has been shown that intensive insulin therapy reduces the development of early atherosclerosis [22] . Therefore, sensitivity analysis was done on the effect of intensive therapy on the incidence of stroke and AMI. We carried out one set of analyses assuming that it would reduce the diabetes-attributed risk of stroke and AMI p, annual probability; hypo, hypoglycaemic event; a two different values were tested for the effect of intensive therapy on macrovascular disease; b assumption by 41 % and another that assumed there would be no impact of intensive therapy on incidence of stroke or AMI. Additional sensitivity analyses were done. One-way sensitivity analysis on life expectancy and total costs for patients treated with I + EYE + ACE was done to identify factors exerting a major influence on these outcomes. Each cost and probability variable was varied one at a time by + /-10 % while holding all other variables constant, and the effect on outcomes was observed. Threshold (break-even) analysis was done on the annual costs of intensive insulin therapy. This is a specialized form of one-way sensitivity analysis in which the annual costs of intensive insulin therapy were varied until the total lifetime costs (costs of therapy + costs of treating events) were equal to the total costs for conventional therapy.
The sub±model structures
The full model structure was built up from a series of sub-models that simulate the progression of the seven important complications of diabetes considered. The sub-models were run in parallel, allowing the cohort to develop more than one complication simultaneously, reflecting real-life. Each sub-model was a Markov model using time-and state-dependent probabilities. The calculation cycle was 1 year. Overall mortality for the complete model was calculated by integrating complication-specific mortality calculated within each sub-model with non-complication-specific mortality [23] . The model was programmed using TOM (Tools for Outcomes Modeling) software from IMIB (Basel/Riehen, Switzerland).
Nephropathy sub-model. Diabetic nephropathy begins without clinical symptoms and, without intervention, can progress to end stage renal failure. The nephropathy sub-model simulated the progression from no renal complications to end stage renal disease (ESRD) (Fig. 1A ). The cohort started in the state of ªno microalbuminuriaº (no MAU) [defined as a urinary albumin excretion rate (UAE) < 40 mg/24 h], to the state of ªMAUº (defined as UAE rate of 40±300 mg/24 h). The rate of progression from ªno MAUº to ªMAUº was dependent on the cohort's baseline HbA 1c value [24] and duration of diabetes [9] . The rate of progression from ªno MAUº to ªMAUº is decreased by intensive therapy [9] . From the state of ªMAUº, the patient may progress to the state of ªmacroalbuminuriaº defined as a UAE rate of more than 300 mg/24 h. The rate of progression from ªMAUº to ªmacroalbuminuriaº with conventional therapy is calculated using a mean 20 % annual increase in UAE [4] . The annual increase in UAE is decreased independently by both intensive insulin therapy and the use of ACE-I (by 55 %), independent of antihypertensive effects [9, 25±27] . From the state of ªmacroalbuminuriaº, the cohort could progress to ESRD. The rate of progression from ªmacro-albuminuriaº to ESRD is dependent on the duration of macroalbuminuria [28] , and is decreased (by 50 %) by the use of ACE-I [29] . The DCCT did not investigate the effect of intensive therapy on progression from macroalbuminuria to ESRD, and so it was conservatively assumed that it has no effect. When ESRD is reached, the cohort requires renal replacement therapy. Patients receive either haemodialysis (80 %), peritoneal dialysis (15 %), or kidney transplant (6 %) [18] . Patients with ESRD have a probability of death that is dependent on the type of renal replacement therapy they received [30, 31] . Of those patients who received a kidney transplant, there is a time±dependent probability of graft failure, in which case the patient is transferred to either peritoneal or haemodialysis [31] .
Retinopathy sub±model. Diabetic retinopathy is the leading cause of blindness in patients 25 to 74 years of age [32] , and accounts for 12 % of all new cases of blindness in the USA [33] . The basic pattern of progression is from no retinopathy, to background retinopathy, to proliferative retinopathy, and finally to blindness (Fig. 1B) . The rate of progression from ªno retinopathyº to the background retinopathy is dependent on the duration of diabetes and the HbA 1 c value and is reduced (by 76 %) with intensive insulin therapy [9, 34] . From background retinopathy, the patient can progress to proliferative retinopathy. The rate of progression to proliferative retinopathy is dependent on duration of diabetes, HbA 1 c value, and is reduced (by 47 %) with intensive therapy [9, 34, 35] . The retinopathy sub-model differentiates between patients who are screened annually for retinopathy using 7-field fundus photography and those who are not screened. It is assumed that those patients who are screened will be treated with laser therapy, if proliferative retinopathy is detected. The rate of progression from proliferative retinopathy to blindness is reduced by 90 % in patients treated with laser therapy [36] .
AMI sub±model. Diabetic patients are at a two± to fourfold increased risk of AMI compared with the non-diabetic population [37] . The probability of having a first AMI depends on the patient's age, sex, smoking status, SBP, HDL, T-CHOL, and presence of left ventricular hypertrophy [38] . Approximately 6±10 % of patients having a first AMI die immediately. The probability of immediate death depends on sex and age [39, 40] . Those who survive the first hour are admitted to hospital, where the treatment options are either primary percutaneous transluminal coronary angioplasty (PTCA), thrombolysis, or no reperfusion therapy (i. e. intensive drug therapy). The probability of in-hospital death depends on the therapy re- Stroke sub±model. Diabetic patients are at double the risk of stroke compared with patients without diabetes [37] . The probability of a first stroke is dependent on age, SBP, use of anti-hypertensive therapy, smoking status, a history of other cardiovascular disease (includes history of myocardial infarction, angina pectoris, coronary insufficiency, cardiac failure, and intermittent claudication), presence of atrial fibrillation, and presence of left ventricular hypertrophy [43] . Approximately 5 % of diabetic patients having a first stroke die immediately [44] . Approximately 16 % of diabetes patients admitted to hospital die in-hospital. The probability of in-hospital death depends on the patient's sex [44] . Those patients surviving the in-hospital period have a sex-dependent probability of death in the first year following the first stroke [44] . The subjects surviving the first year after the first stroke progress to the state of ªhistory of strokeº. Now the patient has an annual sex-and time-dependent probability of dying [44] . The surviving patients have an annual sex-and time-dependent probability of recurrent stroke (Fig. 2B) [45] .
Amputation sub±model. Patients with diabetes have a 14 times higher risk of non-traumatic lower extremity amputation compared with the population without diabetes [46] . Peripheral neuropathy increases the risk of lower extremity amputation primarily through an increased tendency of the diabetic patient to have unrecognized cutaneous damage through trauma and pressure. Peripheral neuropathy increases the risk of lower extremity trauma through inhibited proprioception of the lower limb joints. Macrovascular disease impairs peripheral arterial circulation, with poor healing of damaged skin, chronic ulceration and infection. The combination of these factors independently contributes to an increased risk of non±traumatic amputation in diabetic patients [47] . The probability of amputation is subjet to age, sex, smoking status and blood pressure [46, 48, 49] . Due to the significant reduction of the incidence of peripheral neuropathy (by 60 %) with intensive therapy, as well as a trend towards reduction of the incidence of macrovascular events (by 41 %), the probability of amputation was assumed to be decreased by 41 % with intensive therapy. Following ini- A B C tial amputation, the annual incidence of re-amputation is four times higher than that of first amputation [46, 49] . Patients have an increased risk of death once amputation has occurred. This includes intra-operative death, which may range between 1 % and 10 % depending on the site of amputation (Fig. 2C ).
Hypoglycaemia sub±model. Diabetic patients often experience episodes of hypoglycaemia, most of which require no external assistance and are treated by ingestion of oral glucose. In some cases, hypoglycaemia requires external medical assistance and could lead to loss of consciousness, coma or death.
In the DCCT, the risk of hypoglycaemia with intensive insulin therapy was increased approximately three times in comparison with conventional therapy [9] . Additionally, the risk of a major hypoglycaemic event is increased by 2.8 times in Type I diabetic patients treated with ACE inhibitors [51] . Although no patients died due to hypoglycaemic events, severe hypoglycaemia is generally regarded as life-threatening, and we assumed a case fatality probability of 0.0001 in our model (Fig. 3A) .
Ketoacidosis sub-model. Patients could experience an episode of ketoacidosis. Patients having an episode of ketoacidosis have a case fatality rate of 5 % [52] , although only one patient was reported to have died from ketoacidosis in the DCCT (Fig. 3B) , [9] .
Results
The mean expected total lifetime costs per patient, the life expectancy from baseline age, and the incremental cost-effectiveness ratio (costs per life-year gained) are summarized (Table 3) . Total lifetime costs and life expectancy under the two different assumptions regarding the effect of intensive insulin therapy on macrovascular disease discussed previously are shown. The effect of using different discount rates on mean expected total lifetime costs and lifeyears gained compared with conventional therapy alone are summarized ( Table 4) .
The contribution of different interventions and complications to the mean expected lifetime costs per patient was analysed (Table 5) . With conventional insulin therapy alone, the major cost driver was the cost of renal failure. These costs are substantially reduced with the addition of screening for MAU and appropriate ACE therapy. For intervention strate-A B Fig. 3 . Hypoglycaemia sub-model (A), ketoacidosis sub-model (B) EYE, screening for proliferative retinopathy, followed by laser therapy if detected; ACE, screening for microalbuminuria, followed by angiotensin converting enzyme inhibitor therapy if detected; TC, mean expected total lifetime costs per patient, undiscounted; CLYG, costs per life year gained in comparison to conventional therapy alone; +, assumes reduction in attributed risk of myocardial infarction and stroke due to diabetes of 41 % with intensive therapy; -, assumes no effect of intensive therapy on myocardial infarction and stroke incidence; D, dominant strategy EYE, screening for proliferative retinopathy, followed by laser therapy if detected; ACE, screening for microalbuminuria, followed by angiotensin converting enzyme inhibitor therapy if detected; The addition of screening and treatment for retinopathy has no effect on life expectancy gies, including intensive insulin therapy, the main cost driver is intensive therapy itself, although this is offset to some extent by the reduction in the costs due to renal disease, amputation, and blindness. Survival functions, cumulative incidence of ESRD, blindness, and amputation over the simulation period were calculated. The survival curves are shifted to the right with ACE therapy due to the reduction in excess mortality from renal failure in the period of 25 years from baseline age. Intensive therapy has a greater shift to the right than ACE inhibitor therapy due to the additional effect of reduced amputation, AMI and stroke. The combination of intensive and ACE therapy shows the maximal effect on survival function. Intervention strategies including retinopathy screening and treatment are not shown as they have no effect on survival (Fig. 4) . Addition of ACE therapy to conventional therapy has a greater effect than intensive therapy on reducing cumulative incidence of ESRD. In this study, the effect of intensive therapy is possibly underestimated because of the assumption that it would have no effect on progression from proteinuria to renal failure. The combination of intensive insulin therapy and ACE could almost eliminate the development of ESRD (Fig. 5A) .
Without any additional intervention, blindness will occur in approximately 42 % of patients by the age of 50 years. Intensive therapy alone will reduce this to 7 %, addition of screening and laser therapy to conventional therapy will reduce this to less than 10 %, and the combination of intensive therapy plus screening and laser therapy will have the optimal effect by reducing cumulative incidence of blindness at age 50 years to less than 2 % (Fig. 5B) .
The cumulative incidence of first amputation is reduced from approximately 30 % with conventional therapy to 22 % with intensive insulin therapy alone. Paradoxically, the addition of ACE to intensive therapy increases the cumulative incidence of amputation. This effect on cumulative incidence is also seen in AMI and stroke with intensive therapy or ACE treatment or both. This is because the patients in the cohorts treated with intensive therapy or ACE or both have a greater life expectancy, exposing these surviving patients to the increasing risk of macrovascular events associated with increasing age (Figs. 6A-6C). By age 50 patients have experienced 5, 15, 17, and 30 major hypoglycaemic events under conventional therapy alone, conventional plus ACE, intensive, and intensive plus ACE, respectively (Fig. 7) .
One-way sensitivity analysis showed that the annual cost of intensive therapy had the greatest impact on the total lifetime costs in patients treated with a combination of intensive insulin therapy, eye, and MAU screening and treatment. Reduction in diabetes-attributed risk of AMI and reduction in incidence and progression of MAU with intensive insulin therapy had the greatest impacts on life expectancy (Figs.  8, 9 ). Break-even analysis of the annual costs of intensive insulin therapy, either alone or in combination with eye and MAU screening strategies, were Swiss francs (CHF) 3 130 and CHF 2 960 per year respectively (Fig. 10) .
Discussion
The addition of annual screening for MAU or retinopathy or both to conventional insulin therapy leads to cost savings and, in the case of MAU screening and ACE treatment, to an improvement of life expectancy. Therefore, these intervention strategies are regarded as ªdominantº to conventional therapy alone in health economic terms. These results correspond to those of other cost-effectiveness studies of screening for MAU and retinopathy [4, 53] . In terms of clinical outcomes (life expectancy and reduction of complications), the optimal management strategy most likely to lead to the attainment of Saint Vincent Declaration targets [54] is a combination of intensive insulin therapy, including regular, frequent self monitoring of blood glucose, 3±monthly HbA 1 c monitoring, and regular screening for early complications and appropriate treatment if the complications are detected. This is achieved with only moderate in- Cumulative events per patient of major hypoglycaemia. Circles, C; diamonds, C + ACE; triangles, I; squares, I + ACE Fig. 8 . One±way sensitivity analysis on total lifetime costs. The central vertical line represents the total lifetime costs for intensive therapy calculated using the baseline cost and probability estimations (Tables 1, 2) . Each parameter was varied one at a time by +/-10 %. The relative size of the impact is represented by the relative width of the corresponding horizontal bar creases in total direct costs, representing good costeffectiveness when rated on international scales (Table 3) [55, 56] . These results correspond well to those generated in another long-term modelling study that showed an improvement in life expectancy of 5.1 years with intensive therapy combined with ACE therapy and an incremental cost-effectiveness ratio of $US 28 661 per life±year gained (outcomes discounted at 3 % per annum) [6] . Whereas the strategy I + EYE + ACE leads to the greatest improvement in life expectancy and reduction in long-term complications, the strategy C + EYE + ACE, with both costs savings and improved life expectancy (although a lesser improvement in life expectancy than with I + EYE + ACE) could be considered more efficient. The incremental cost-effectiveness ratio of I + EYE + ACE vs C + EYE + ACE is CHF 133 174 if both costs and life±years gained are discounted at 3 % (range: CHF 9 009 if costs discounted at 6 %, life±years gained not discounted, to CHF 441 128 if costs not discounted and life±years gained discounted at 6 %). The current analysis does not assess the effect of interventions on quality-adjusted life expectancy (see below) and thus possibly underestimates the effect of intensive insulin therapy on quality of life due to complications such as neuropathy/amputation, and possibly stroke and AMI, being avoided. While C + EYE + ACE appears more attractive from a purely economic point of view, a primary goal of a health care system is to prevent the preventable. The ethical question of first waiting until patients develop microvascular complications, then treating them, needs to be addressed elsewhere.
A recent survey of Swiss patients with diabetes [57] , showed that among Type I patients only 67 % regularly monitor their blood glucose concentrations (frequency per day not specified), 68 % had a HbA 1 c measurement within the last 6 months, 3 % had a measurement of UAE within the last 6 months, and 84 % had a funduscopic examination in the last 12 months. Clearly there is room for improvement in the management of Type I diabetic patients in Switzerland. The fact that only 3 % of Type I patients had their UAE monitored in the previous 6 months is of particular concern, considering the potential to avoid morbidity and mortality associated with renal disease with early recognition and appropriate intervention
The direct costs of blindness due to diabetic retinopathy are not known in Switzerland. An estimate of CHF 1000 was used as the annual direct costs of blindness per patient. This estimate is conservative because the costs per patient for training, special appliances and aids are approximately CHF 24 000 to Fig. 9 . One±way sensitivity analysis on life expectancy. The central vertical line represents the life expectancy for intensive therapy calculated using the baseline probability estimations (Table 1) . Each parameter was varied one at time by +/-10 %. The relative size of the impact on life expectancy is represented by the relative width of the corresponding horizontal bar Fig. 10 . Break-even analysis of the annual costs of intensive insulin therapy. Horizontal line = total lifetime costs per patient treated with conventional insulin therapy alone. Diagonal line = lifetime costs for patients treated with intensive therapy alone (darker line) or I + EYE + ACE (lighter line) as the annual costs of intensive therapy is varied from CHF 2 000 to CHF 5 000. Intersection points = break±even values for the annual costs of intensive insulin therapy. If the annual costs of intensive insulin therapy are less than CHF 2 960 per year, the total lifetime costs per patients will be lower than those of patients treated with conventional therapy alone. CHF, Swiss francs 54 000 (personal communication, Association of the Blind and Visually Impaired, Bern, Switzerland), although not all of these costs would be borne by the health insurance company. Thus, it is possible that the cost savings for blindness avoided by screening for and treatment of proliferative retinopathy and intensive therapy are underestimated in this analysis.
The life expectancies projected by the model under conventional therapy alone correspond closely to those reported recently for a German population in which diabetic patients with an age of onset of less than 30 years had life expectancies of 52.3 years [58] .
The major clinical disadvantage of intensive insulin therapy and ACE therapy is the increased incidence of major hypoglycaemia. The risk of major hypoglycaemia is increased 3 times with intensive therapy and 2.8 times with ACE treatment. The model assumes that the increase in risk due to these two interventions is independent and multiplicative, although the interactions in real life are not known and need to be confirmed by empirical observation. The increase in total costs due to major hypoglycaemic events is relatively small compared with the cost savings gained by the reduction of other complications (Table 5) .
Intensive insulin therapy was conservatively assumed to have no effect on the progression from proteinuria to ESRD. In reality, it is possible that intensive therapy reduces progression of proteinuria, in which case the effects of intensive therapy on reducing ESRD have been underestimated by the model. Screening for proliferative retinopathy was assumed to be by 7-field fundus photography on an annual basis. Other screening methods, like dilated ophthalmoscopy or other time intervals for screening that may also be cost-effective were not compared in this analysis [53, 59] .
There was controversy as to which discount rate to apply [7, 8] thus the effect of three different discount rates was analysed (Table 4) . Discounting takes into account the time preference for money and health improvements. Secondary screening and treatment, and particularly intensive insulin therapy, require a relatively high level investment in the short-term. The pay-off from these additional interventions is not seen until after 10±15 years when a reduction in costly complications, particularly renal disease, is seen relative to conventional insulin therapy. The decrease in lifeyears gained compared with conventional therapy seen with increasing discount rates reflects the predominantly long-term clinical benefits seen with the interventions analysed. Intervention strategies including intensive insulin therapy become less attractive from the health-economic viewpoint as higher discount rates for clinical and economic outcomes are applied.
Inclusion of indirect costs in health economic analyses is controversial [60] . Indirect costs are often not included in health-economic analyses, despite country-specific recommendations [8, 61] . Reasons for exclusion of indirect costs include the perspective of the payer taken, controversy over the methodology used to calculate indirect costs [60] and difficulty in accurate accounting [62] . In our analysis, where the perspective of the health insurance payer was taken and where no data were available, indirect costs were not included in the analysis.
Lifetime costs were most sensitive to variation of the annual costs of intensive insulin therapy. Variations of the costs per major hypoglycaemic event also had an impact because of the higher frequency of hypoglycaemic events seen in the combination of intensive insulin and ACE therapy. Variations in the costs of ªend-stageº complications, such as blindness, renal failure, AMI and stroke had relatively little impact on total cost outcomes because of the less frequent occurrence of these complications with a combination of intensive insulin therapy, MAU and eye screening and treatment.
The break-even point for the annual costs of intensive insulin therapy was approximately CHF 3000 compared with the current costs of CHF 4936 per year. If intensive insulin therapy could be implemented with an annual cost below this break-even point, overall cost savings would be seen.
The validity of all clinico-economic analyses is limited by the availability of appropriate medical and cost data. The data available from the literature are themselves limited by the aims, populations, and methodology of the clinical trials that generate the data. For the comparison of conventional and intensive insulin therapies, the model takes DCCT data from the USA and assumes that intensive therapy can be implemented in the Swiss population with similar effectiveness. The DCCT population was a select population that was highly motivated, with a high intelligence quotient and relatively well educated [63] . This possibly does not reflect the general Type I diabetic population either in the USA or in Switzerland. As it is unlikely, however, that a DCCT-like trial will ever be repeated, either in Switzerland or the USA, the available data must be used.
Possible effects of ACE inhibitors on reducing incidence and progression of other complications including retinopathy [64±66], neuropathy [67, 68] , and improved survival after AMI [69±72] were not taken into account. Similarly, possible improvements in survival post-AMI seen with intensive therapy [73] were also not considered in the model. Other important interventions such as intensive blood pressure control [74] , aspirin for primary and secondary cardiovascular disease prevention [75] smoking cessation programmes, and lipid modification, were not explicitly modelled.
Measures of dispersion of the results were not calculated for a number of reasons. Firstly, for an accurate estimation of confidence intervals each probabil-ity and cost item needs to be defined as a distribution. In reality, it is difficult to find probabilities and costs even as single (point value) numbers and distributions are rarely reported. Therefore, distributions must be artificially created or assumed, leading to the calculation of artificial confidence intervals that may or may not reflect reality. Secondly, in a complex model, even if distributions for probabilities and costs were available, the usual methods for calculation of variance, such as first and second order Monte Carlo simulation would take an estimated 3±4 weeks per simulation. Thus, the more than 30 separate simulations that were necessary for the current study would have taken as long as 2 years to run. The model was designed to give results within minutes rather than weeks to allow the speedy exploration of different data sets or assumptions in the real-time setting.
Finally, quality of life changes were not explicitly assessed in the analysis. Despite the rigors of intensive insulin therapy and the increased risk of hypoglycaemia, quality of life did not deteriorate in the intensively treated patients of the DCCT, although patients with three or more severe hypoglycaemic events were at an increased risk of measurable psychological distress [76] . Furthermore, it is implicit that interventions leading to a reduction in the incidence and progression of irreversible complications would lead to an improvement in quality of life.
Disease modelling allows the estimation of longterm prognoses based on available data. In the absence of population trials or observational studies, the model can be thought of as generating hypotheses requiring confirmation rather than providing definitive answers. Within these limitations, tentative conclusions can be drawn. Generally, the addition of screening for microalbuminuria and retinopathy and, if detected, followed by appropriate treatment is likely to be cost saving, with a reduction in the cumulative incidence of end stage renal disease and blindness respectively. In the case of MAU screening and treatment, an improvement in life expectancy is likely. The strategy C + EYE + ACE is most efficient in economic terms but the strategy I + EYE + ACE is the intervention strategy most likely to achieve St. Vincent Declaration targets, with improved life expectancy and decreased long-term diabetes complications, but with increased lifetime costs.
